SME Times is powered by   
Search News
Just in:   • Hanwha Aerospace wins $1.9 billion Norway rocket deal  • Ajit Pawar, five others die in plane crash in Baramati, confirms DGCA  • Sensex up over 500 points, Nifty crosses 25,350 buoyed by India-EU FTA  • India-Italy ties set on path of rapid expansion: Italian President  • Sensex, Nifty end higher as India-EU trade deal boosts sentiment 
Last updated: 01 Feb, 2017  

cadila.thumb.jpg Cadila Healthcare net profit declines 34.6 pc in Q3

cadila.jpg
   Top Stories
» Sensex up over 500 points, Nifty crosses 25,350 buoyed by India-EU FTA
» Sensex, Nifty end higher as India-EU trade deal boosts sentiment
» EU trade deal biggest in India's history, to create huge opportunities: PM Modi
» PM Modi inaugurates IEW 2026; announces 'significant' India-EU trade development
» Sensex, Nifty open lower as investors await India-EU FTA
SME Times News Bureau | 01 Feb, 2017
Global pharmaceutical company Cadila Healthcare on Tuesday posted a 34.6 percent decline in its consolidated net profit to Rs 281.6 crore for the quarter ended December 31, 2016 as compared with Rs 430.5 crore in the year-ago period.

The company's consolidated total income from operations also dipped to Rs 2,363.8 crore during the quarter under review as compared with Rs 2,408.9 crore in a year-ago period.

On BSE, the stock settled at Rs 349.25, down 7.02 percent from the previous close.
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
₹91.2
₹89.5
UK Pound
₹123.35
₹119.35
Euro
₹107
₹103.35
Japanese Yen ₹57.9 ₹56.1
As on 22 Jan, 2026
  Daily Poll
Will the India-EU "Mother of All Deals" help your MSME?
 Yes - Alternative To US
 No - EU Compliance is hard
 Maybe - if the fine print is small biz ready
 Not Sure - Need to See Final Text
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter